Volume 67, Issue 1, Pages (January 2005)

Slides:



Advertisements
Similar presentations
Volume 62, Issue 6, Pages (December 2002)
Advertisements

Volume 82, Issue 12, Pages (December 2012)
Optimization of pre-ESRD care: The key to improved dialysis outcomes
Volume 54, Issue 2, Pages (August 1998)
Acute interstitial nephritis
Urinary ammonia and long-term outcomes in chronic kidney disease
Volume 92, Issue 5, Pages (November 2017)
Volume 85, Issue 5, Pages (May 2014)
Mitchell H. Rosner, W. Kline Bolton  Kidney International 
No difference in bleeding risk between subcutaneous enoxaparin and heparin for thromboprophylaxis in end-stage renal disease  Kevin E. Chan, Ravi I. Thadhani,
Volume 83, Issue 3, Pages (March 2013)
Acute interstitial nephritis
Volume 61, Issue 2, Pages (February 2002)
Volume 80, Issue 1, Pages (July 2011)
Volume 82, Issue 12, Pages (December 2012)
Volume 86, Issue 4, Pages (October 2014)
The progression of chronic kidney disease: A 10-year population-based study of the effects of gender and age  B.O. Eriksen, O.C. Ingebretsen  Kidney International 
The clinical spectrum of tubulointerstitial nephritis
Volume 92, Issue 1, Pages (July 2017)
Volume 79, Issue 12, Pages (June 2011)
Volume 63, Issue 4, Pages (April 2003)
Steven G. Coca, Swathi Singanamala, Chirag R. Parikh 
Volume 75, Issue 12, Pages (June 2009)
Comorbidity and confounding in end-stage renal disease
Volume 70, Issue 11, Pages (December 2006)
Renal risk scores: Progress and prospects
A novel classification for IgA nephropathy
Long-term study of mycophenolate mofetil treatment in IgA nephropathy
Takashi Ehara, Hidekazu Shigematsu  Kidney International 
Volume 85, Issue 6, Pages (June 2014)
Volume 76, Issue 10, Pages (November 2009)
Volume 61, Issue 4, Pages (April 2002)
Volume 70, Issue 12, Pages (December 2006)
Volume 67, Pages S48-S51 (January 2005)
Fructose intake as a risk factor for kidney stone disease
Volume 62, Issue 1, Pages (July 2002)
The Case | Idiopathic hypocomplementemic interstitial nephritis
Volume 70, Issue 6, Pages (September 2006)
Linda F. Fried, Trevor J. Orchard, Bertram L. Kasiske 
Volume 71, Issue 6, Pages (March 2007)
Counteracting progression of renal disease: A look into the future
Volume 80, Issue 6, Pages (September 2011)
Volume 79, Issue 2, Pages (January 2011)
Homocysteine, renal function, and risk of cardiovascular disease
Volume 82, Issue 3, Pages (August 2012)
The treatment of acute interstitial nephritis: More data at last
Endothelin antagonists in renal disease
Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors  Barry M. Brenner, Joann Zagrobelny 
Kathy E. Sietsema, Antonino Amato, Sharon G. Adler, Eric P. Brass 
Low triiodothyronine and survival in end-stage renal disease
Overview of the cellular and molecular basis of kidney fibrosis
The Danish Renal Biopsy Register
Volume 80, Issue 10, Pages (November 2011)
ANCA-associated glomerulonephritis in the very elderly
Volume 60, Issue 3, Pages (September 2001)
Class IV-S versus class IV-G lupus nephritis: Clinical and morphologic differences suggesting different pathogenesis  Gary S. Hill, Michel Delahousse,
Robert G. Nelson, Hal Morgenstern, Peter H. Bennett 
Michael R. Lattanzio, Matthew R. Weir  Kidney International 
Volume 75, Issue 1, Pages (January 2009)
Volume 53, Issue 5, Pages (May 1998)
The more or less ‘pristine’ renal allograft biopsy
Volume 63, Pages S13-S16 (February 2003)
Giuseppe Remuzzi, Carlos Chiurchiu, Piero Ruggenenti 
Volume 75, Issue 7, Pages (April 2009)
Volume 64, Issue 4, Pages (October 2003)
Predictive value of urinary micro-cholesterol (mCHO) levels in patients with progressive glomerular disease  Osamu Hotta, Hisako Sugai, Hiroshi Kitamura,
Optimization of pre-ESRD care: The key to improved dialysis outcomes
Volume 67, Issue 4, Pages (April 2005)
Volume 57, Pages S44-S48 (April 2000)
Volume 68, Issue 4, Pages (October 2005)
Presentation transcript:

Volume 67, Issue 1, Pages 94-102 (January 2005) Quantitative morphometry of lupus nephritis: The significance of collagen, tubular space, and inflammatory infiltrate  Michael G. Hunter, Shelley Hurwitz, Christopher O.C. Bellamy, Jeremy S. Duffield, Dr  Kidney International  Volume 67, Issue 1, Pages 94-102 (January 2005) DOI: 10.1111/j.1523-1755.2005.00059.x Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 1 Comparison of original light images with digitally analyzed micrographic images (×1000). Original bright field image stained with picro-Sirius red (A) has been digitized to highlight tubular space in red, but to exclude no biopsy area in blue (B). Nuclei alone (C) and nuclei plus Sirius red–positive material are highlighted (D). The original image was viewed by double polarized light (E) with the digitized image highlighting fibrillary collagen for comparison (F). Kidney International 2005 67, 94-102DOI: (10.1111/j.1523-1755.2005.00059.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 2 Correlation of nuclear index with clinical parameters at the time of biopsy. Correlation curves demonstrate positive correlation with proteinuria (r = 0.40, P < 0.05) (A). Negative correlation of nuclear index with creatinine clearance (r=-0.34, P < 0.05) (B). Negative correlation plasma albumin (r=-0.55, P < 0.01) (C). Kidney International 2005 67, 94-102DOI: (10.1111/j.1523-1755.2005.00059.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 3 Survival plot of the proportion without doubling of serum creatinine as a function of time from biopsy according to fibrillary collagen index split at the median. There was a significant interaction between the fibrillary index and follow-up time (P = 0.01). After 60 months, the hazard ratio for a high fibrillary index in predicting progressive disease was 5.2. Kidney International 2005 67, 94-102DOI: (10.1111/j.1523-1755.2005.00059.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 4 Survival plot of the proportion without reaching end-stage renal disease (ESRD) as a function of time from biopsy according to collagen matrix index. Those patients with higher than the median collagen matrix index (26.4%) at presentation exhibited more rapid progression to ESRD compared with a lower index with a sixfold greater risk [hazards ratio (HR) 6.4; 95% confidence interval (95% CI) 0.7, 57; P = 0.06]. Kidney International 2005 67, 94-102DOI: (10.1111/j.1523-1755.2005.00059.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 5 Survival plot of the proportion without doubling serum creatinine as a function of time according to the tubular index. The proportional hazards assumption was rejected as there was a significant interaction between the original tubular index values and follow up time (P = 0.05). Those patients with higher than median tubular index (11.7%) exhibited more rapid progression to doubling of creatinine with 2.5 times the risk compared with those patients lower than the median. This difference was not significant, however [hazards ratio (HR) 2.5; 95% confidence interval (95% CI) 0.8, 7.9; P = 0.1). Kidney International 2005 67, 94-102DOI: (10.1111/j.1523-1755.2005.00059.x) Copyright © 2005 International Society of Nephrology Terms and Conditions